BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,420,526 | -12.6% | 53,869 | -43.0% | 0.08% | -9.2% |
Q2 2023 | $1,624,798 | +93.0% | 94,465 | +86.1% | 0.09% | +67.3% |
Q1 2023 | $841,816 | +537.7% | 50,773 | +249.0% | 0.05% | +550.0% |
Q2 2022 | $132,000 | -21.4% | 14,549 | -11.9% | 0.01% | +14.3% |
Q1 2022 | $168,000 | -45.1% | 16,523 | -10.0% | 0.01% | -30.0% |
Q4 2021 | $306,000 | -68.7% | 18,362 | -12.1% | 0.01% | -69.7% |
Q3 2021 | $979,000 | – | 20,879 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |